G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes
Xiaoxin X. Wang(Beijing Obstetrics and Gynecology Hospital), Moshe Levi(University of Colorado Anschutz Medical Campus), Jeffrey B. Kopp(National Institute of Diabetes and Digestive and Kidney Diseases), Jonathan Levi(National Institutes of Health), Yuhuan Luo(University of Colorado Anschutz Medical Campus), Moin A. Saleem(University of Bristol), Evgenia Dobrinskikh(University of Colorado Anschutz Medical Campus), Luciano Adorini(Intercept Pharmaceuticals (United States)), Uzi Gafter(Tel Aviv University), Michal Herman Edelstein(Tel Aviv University), Scott Lucia(University of Colorado Anschutz Medical Campus), Liru Qiu(University of Colorado Anschutz Medical Campus), Avi Z. Rosenberg(Johns Hopkins University), Vivette D. D’Agati(Columbia University), David Gius(The University of Texas at San Antonio Health Science Center)
Cited by 208
Related Papers
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
|The Lancet|2000|1k
Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices
|Kidney International|2018|1k
APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy
|Journal of the American Society of Nephrology|2011|856
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis
|Nature Medicine|2011|834
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis
|Nature Genetics|2008|706